Some of My Favorite Things from #IMFASH19

Robin Tuohy |

Hello everyone, since it’s that time of year when we are thinking about “All of Our Favorite Things,” I thought it would be nice to share with you just a glimpse of some of my favorite things from at ASH. These are in no particular order, except chronological, so I can think about each day’s […]

Cindy Chmielewski on ASH background

Immunotherapy – Front and Center

Cynthia Chmielewski |

Immunotherapy was front and center at this year’s American Society of Hematology’s (ASH) meeting. There even was an Education Session presented by Drs. Shah, Cohen and Borello on this topic. When I first attended the ASH Annual Meeting in 2012, immunotherapy was still in its infancy. The treatments that were being examined in clinical trials back […]

John Deflice, myeloma patient, with backdrop of ASH conference in Orlando 2019

“Baby, baby, baby what will it be?” —Prince

John DeFlice |

With so many great studies covered at ASH 2019, what will take home the honors for the best outstanding oral presentation? Will it be a Chimeric Antigen Receptor (CAR) or Bispecific T-cell Engager (BiTEs) trials, or will it be a new four-drug combination trial? How about one study that has a 100% response rate in myeloma […]

Day 3 – “Myeloma Monday” Saving the Best for Last

Jack Aiello |

Before providing details of our final full day at ASH (noting #abstract where applicable), let me review some activities from yesterday (Sunday 12/8/19). In the morning I attended a number of myeloma cancer care delivery abstracts (#383, #423, #424) where topics like diversity and racial/socioeconomic impact were discussed. Black/African-American patients are less likely to have […]

Immunotherapy at #ASH19

Jim Omel |

Immunotherapy has definitely been the center of myeloma attention at ASH. Sessions on Bi-specific T-cell Engagers and CAR-T were many and were well attended. Several Chinese oral abstract presentations Monday morning were inspiring and promising. Deepu Madduri, MD, showed a waterfall plot with 100% response rate in a phase I/phase II study of JNJ4528 BCMA-Targeted CAR-T cell […]

Taking a BiTE Out of Myeloma

Michael Tuohy |

I have been a multiple myeloma patient and advocate for 19 years. Time sure flies by! As I reflect back on what treatments were available in 2000 when I was diagnosed, I am eternally grateful for all the progress and interest in multiple myeloma! I’d also like to recognize all the patients that have participated in clinical […]